US4327725A
(en)
|
1980-11-25 |
1982-05-04 |
Alza Corporation |
Osmotic device with hydrogel driving member
|
DE3303707A1
(en)
|
1983-02-04 |
1984-08-09 |
Dynamit Nobel Ag, 5210 Troisdorf |
METHOD FOR CLEAVING ORGANOSILOXANES AND ITS PRODUCTS AND APPLICATIONS
|
US4624848A
(en)
|
1984-05-10 |
1986-11-25 |
Ciba-Geigy Corporation |
Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use
|
US4968509A
(en)
|
1987-07-27 |
1990-11-06 |
Mcneilab, Inc. |
Oral sustained release acetaminophen formulation and process
|
US5052558A
(en)
|
1987-12-23 |
1991-10-01 |
Entravision, Inc. |
Packaged pharmaceutical product
|
US5033252A
(en)
|
1987-12-23 |
1991-07-23 |
Entravision, Inc. |
Method of packaging and sterilizing a pharmaceutical product
|
JPH01167840A
(en)
|
1987-12-24 |
1989-07-03 |
Konica Corp |
Novel photographic cyan coupler
|
IL92966A
(en)
|
1989-01-12 |
1995-07-31 |
Pfizer |
Dispensing devices powered by hydrogel
|
US5145684A
(en)
|
1991-01-25 |
1992-09-08 |
Sterling Drug Inc. |
Surface modified drug nanoparticles
|
ES2111065T5
(en)
|
1991-04-16 |
2005-06-16 |
Nippon Shinyaku Company, Limited |
PROCEDURE TO PRODUCE A SOLID DISPERSION.
|
HU227530B1
(en)
|
1991-11-22 |
2011-07-28 |
Warner Chilcott Company |
Delayed-release compositions containing risedronate and process for their production
|
US5461140A
(en)
|
1992-04-30 |
1995-10-24 |
Pharmaceutical Delivery Systems |
Bioerodible polymers for solid controlled release pharmaceutical compositions
|
US5323907A
(en)
|
1992-06-23 |
1994-06-28 |
Multi-Comp, Inc. |
Child resistant package assembly for dispensing pharmaceutical medications
|
US5700410A
(en)
|
1992-10-16 |
1997-12-23 |
Nippon Shinyaku Co., Ltd. |
Method of manufacturing wax matrices
|
GB9226855D0
(en)
|
1992-12-23 |
1993-02-17 |
Erba Carlo Spa |
Vinylene-azaindole derivatives and process for their preparation
|
US5686105A
(en)
|
1993-10-19 |
1997-11-11 |
The Procter & Gamble Company |
Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
|
US6326469B1
(en)
|
1994-04-22 |
2001-12-04 |
Sugen, Inc. |
Megakaryocytic protein tyrosine kinases
|
CA2220451A1
(en)
|
1995-05-17 |
1996-11-21 |
Cedars-Sinai Medical Center |
Methods and compositions for improving digestion and absorption in the small intestine
|
US5593997A
(en)
|
1995-05-23 |
1997-01-14 |
Pfizer Inc. |
4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors
|
US5994348A
(en)
|
1995-06-07 |
1999-11-30 |
Sanofi |
Pharmaceutical compositions containing irbesartan
|
CH690773A5
(en)
|
1996-02-01 |
2001-01-15 |
Novartis Ag |
Pyrrolo (2,3-d) pyrimides and their use.
|
WO1997049706A1
(en)
|
1996-06-25 |
1997-12-31 |
Novartis Ag |
SUBSTITUTED 7-AMINO-PYRROLO[3,2-d]PYRIMIDINES AND THE USE THEREOF
|
SK125999A3
(en)
|
1997-03-19 |
2000-05-16 |
Knoll Ag |
Pyrrolo[2,3d]pyrimidines and their use as tyrosine kinase inhibitors
|
PT901786E
(en)
|
1997-08-11 |
2007-08-07 |
Pfizer Prod Inc |
Solid pharmaceutical dispersions with enhanced bioavailability
|
PT1039909E
(en)
|
1997-12-31 |
2003-02-28 |
Choongwae Pharma Corp |
METHOD OF PRODUCTION AND COMPOSITION OF AN ORAL PREPARATION OF ITRACONAZOLE
|
ES2222705T3
(en)
|
1998-04-17 |
2005-02-01 |
Parker Hughes Institute |
BTK INHIBITORS AND METHODS FOR IDENTIFICATION AND USE.
|
US6303652B1
(en)
|
1998-08-21 |
2001-10-16 |
Hughes Institute |
BTK inhibitors and methods for their identification and use
|
US7122207B2
(en)
|
1998-05-22 |
2006-10-17 |
Bristol-Myers Squibb Company |
High drug load acid labile pharmaceutical composition
|
US6998233B2
(en)
|
1998-06-26 |
2006-02-14 |
Sunesis Pharmaceuticals, Inc. |
Methods for ligand discovery
|
US20050287596A9
(en)
|
1998-06-26 |
2005-12-29 |
Braisted Andrew C |
Novel ligands and libraries of ligands
|
US6335155B1
(en)
|
1998-06-26 |
2002-01-01 |
Sunesis Pharmaceuticals, Inc. |
Methods for rapidly identifying small organic molecule ligands for binding to biological target molecules
|
UA74141C2
(en)
|
1998-12-09 |
2005-11-15 |
Дж.Д. Сірл Енд Ко. |
Oral pharmaceutical compositions comprising micronized eplerenone (variants), method for its production and method for treating aldosterone-mediated states (variants)
|
ATE400252T1
(en)
|
1999-02-10 |
2008-07-15 |
Pfizer Prod Inc |
PHARMACEUTICAL SOLID DISPERSIONS
|
US6306897B1
(en)
|
1999-03-19 |
2001-10-23 |
Parker Hughes Institute |
Calanolides for inhibiting BTK
|
US6395300B1
(en)
|
1999-05-27 |
2002-05-28 |
Acusphere, Inc. |
Porous drug matrices and methods of manufacture thereof
|
CN1390219A
(en)
|
1999-09-17 |
2003-01-08 |
艾博特股份有限两合公司 |
Pyrazolopyrimidines as therapeutic agents
|
US6921763B2
(en)
|
1999-09-17 |
2005-07-26 |
Abbott Laboratories |
Pyrazolopyrimidines as therapeutic agents
|
MXPA02003364A
(en)
|
1999-10-06 |
2002-08-23 |
Boehringer Ingelheim Pharma |
Heterocyclic compounds useful as inhibitors of tyrosine kinases.
|
US6506769B2
(en)
|
1999-10-06 |
2003-01-14 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Heterocyclic compounds useful as inhibitors of tyrosine kinases
|
EP1235567A2
(en)
|
1999-11-30 |
2002-09-04 |
Parker Hughes Institute |
Inhibitors of collagen-induced platelet aggregation
|
IL150059A0
(en)
|
1999-12-17 |
2002-12-01 |
Ariad Pharma Inc |
Novel heterocycles
|
GB0005345D0
(en)
|
2000-03-06 |
2000-04-26 |
Mathilda & Terence Kennedy Ins |
Methods of treating sepsis septic shock and inflammation
|
GB0108903D0
(en)
|
2000-10-05 |
2001-05-30 |
Aventis Pharm Prod Inc |
Novel crystalline forms of a factor Xa inhibitor
|
WO2002038797A2
(en)
|
2000-10-23 |
2002-05-16 |
Bristol-Myers Squibb Company |
Modulators of bruton's tyrosine kinase, their identification and use
|
JP2004514732A
(en)
|
2000-12-06 |
2004-05-20 |
ファルマシア・コーポレーション |
Rapidly dispersing pharmaceutical composition
|
US6465014B1
(en)
|
2001-03-21 |
2002-10-15 |
Isp Investments Inc. |
pH-dependent sustained release, drug-delivery composition
|
MXPA03008560A
(en)
|
2001-03-22 |
2004-06-30 |
Abbot Gmbh & Co Kg |
Single-stage pfc + ballast control circuit/general purpose power converter.
|
US8306897B2
(en)
|
2001-05-04 |
2012-11-06 |
Stockshield, Inc. |
Method and system for insuring against investment loss
|
EP1463742A4
(en)
|
2001-06-21 |
2006-05-10 |
Ariad Pharma Inc |
Novel pyrazolo-and pyrrolo-pyrimidines and uses thereof
|
US20040248906A1
(en)
|
2001-08-10 |
2004-12-09 |
Donato Nicholas J |
Use of c-src inhibitors alone or in combination with st1571 for the treatment of leukaemia
|
JP2005502861A
(en)
|
2001-08-10 |
2005-01-27 |
サイミックス テクノロジーズ, インコーポレイテッド |
Apparatus and method for making and testing pre-formulations and system therefor
|
WO2003016338A1
(en)
|
2001-08-15 |
2003-02-27 |
Parker Hughes Institute |
Crystal structure of the btk kinase domain
|
WO2003046200A2
(en)
|
2001-11-21 |
2003-06-05 |
Sunesis Pharmaceuticals, Inc. |
Methods for ligand discovery
|
US20050084905A1
(en)
|
2002-03-21 |
2005-04-21 |
Prescott John C. |
Identification of kinase inhibitors
|
GB2388594A
(en)
|
2002-05-16 |
2003-11-19 |
Bayer Ag |
Imidazo-triazine PDE 4 inhibitors
|
JP2005536533A
(en)
|
2002-08-08 |
2005-12-02 |
ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド |
Substituted benzimidazole compounds
|
GB0303910D0
(en)
|
2003-02-20 |
2003-03-26 |
Merck Sharp & Dohme |
Therapeutic agents
|
US7687506B2
(en)
|
2003-04-11 |
2010-03-30 |
The Regents Of The University Of California |
Selective serine/threonine kinase inhibitors
|
WO2004100868A2
(en)
|
2003-04-23 |
2004-11-25 |
Abbott Laboratories |
Method of treating transplant rejection
|
EP1473039A1
(en)
|
2003-05-02 |
2004-11-03 |
Centre National De La Recherche Scientifique (Cnrs) |
Use of inhibitors and antisense oligonucleotides of BTK for the treatment of proliferative mastocytosis
|
US7405295B2
(en)
|
2003-06-04 |
2008-07-29 |
Cgi Pharmaceuticals, Inc. |
Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds
|
WO2005005429A1
(en)
|
2003-06-30 |
2005-01-20 |
Cellular Genomics, Inc. |
Certain heterocyclic substituted imidazo[1,2-a]pyrazin-8-ylamines and methods of inhibition of bruton’s tyrosine kinase by such compounds
|
WO2005024043A2
(en)
|
2003-09-03 |
2005-03-17 |
Government Of The United States Of America, As Represented By Secretary, Department Of Health And Human Services |
Methods for identifying, diagnosing, and predicting survival of lymphomas
|
US8131475B2
(en)
|
2003-09-03 |
2012-03-06 |
The United States Of America As Represented By The Secretary, Department Of Health And Human Services |
Methods for identifying, diagnosing, and predicting survival of lymphomas
|
CN1897950A
(en)
|
2003-10-14 |
2007-01-17 |
惠氏公司 |
Fused-aryl and heteroaryl derivatives and methods of their use
|
UA83509C2
(en)
|
2003-10-15 |
2008-07-25 |
Оси Фармасьютикалз, Инк. |
Imidazopyrazines as tyrosine kinase inhibitors
|
US20070196395A1
(en)
|
2003-12-12 |
2007-08-23 |
Mackerell Alexander |
Immunomodulatory compounds that target and inhibit the py'binding site of tyrosene kinase p56 lck sh2 domain
|
US20050153990A1
(en)
|
2003-12-22 |
2005-07-14 |
Watkins William J. |
Phosphonate substituted kinase inhibitors
|
BRPI0418031A
(en)
|
2003-12-22 |
2007-04-17 |
Gilead Sciences Inc |
phosphonate-substituted kinase inhibitors
|
MXPA06007829A
(en)
|
2004-01-08 |
2006-09-01 |
Wyeth Corp |
Directly compressible pharmaceutical composition for the oral admimistration of cci-779.
|
JP2007519742A
(en)
|
2004-01-26 |
2007-07-19 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
Compositions useful as inhibitors of protein kinases
|
WO2005074603A2
(en)
|
2004-02-03 |
2005-08-18 |
Abbott Laboratories |
Aminobenzoxazoles as therapeutic agents
|
ITMI20041314A1
(en)
|
2004-06-30 |
2004-09-30 |
Nuvera Fuel Cells Europ Srl |
COOLING DEVICE FOR MEMBRANE FUEL CELLS
|
MY139689A
(en)
|
2004-07-20 |
2009-10-30 |
Osi Pharm Inc |
Imidazotriazines as protein kinase inhibitors
|
WO2006036941A2
(en)
|
2004-09-27 |
2006-04-06 |
Kosan Biosciences Incorporated |
Specific kinase inhibitors
|
JP2008514700A
(en)
|
2004-09-28 |
2008-05-08 |
ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ |
Substituted dipiperidine CCR2 antagonists
|
MX2007005643A
(en)
|
2004-11-10 |
2008-03-13 |
Cgi Pharmaceuticals Inc |
Imidazo[1 , 2-a] pyrazin-8-ylamines useful as modulators of kinase activity.
|
GB0425035D0
(en)
|
2004-11-12 |
2004-12-15 |
Novartis Ag |
Organic compounds
|
EP1868579B1
(en)
|
2005-03-07 |
2010-09-29 |
Bayer Schering Pharma Aktiengesellschaft |
Pharmaceutical composition comprising an omega-carboxyaryl substituted diphenyl urea for the treatment of cancer
|
ES2543607T3
(en)
|
2005-03-10 |
2015-08-20 |
Gilead Connecticut, Inc. |
Certain substituted amides, method of obtaining, and method of use
|
CN101175753B
(en)
|
2005-05-13 |
2011-03-23 |
Irm责任有限公司 |
Compounds and compositions as protein kinase inhibitors
|
EP2270000B1
(en)
|
2005-05-23 |
2015-07-29 |
Novartis AG |
Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one lactic acid salts
|
EP2395004B1
(en)
|
2005-06-22 |
2016-01-20 |
Plexxikon Inc. |
Pyrrolo [2,3-b]pyridine derivatives as protein kinase inhibitors
|
US20070065449A1
(en)
|
2005-09-16 |
2007-03-22 |
Claire Verschraegen |
Method of treating cancer, especially soft tissue sarcoma utilizing gemcitabine in combination with docetaxel and anti-VEGF therapy (bevacizumab)
|
CA2629314A1
(en)
|
2005-11-12 |
2007-05-24 |
Boehringer Ingelheim International Gmbh |
Tec kinase inhibitors
|
US7625880B2
(en)
|
2006-01-13 |
2009-12-01 |
Pharmacyclics, Inc. |
Inhibitors of tyrosine kinases and uses thereof
|
US20090317836A1
(en)
|
2006-01-30 |
2009-12-24 |
The Scripps Research Institute |
Methods for Detection of Circulating Tumor Cells and Methods of Diagnosis of Cancer in Mammalian Subject
|
JP2009530415A
(en)
|
2006-03-20 |
2009-08-27 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
Pharmaceutical composition
|
KR20150038395A
(en)
|
2006-04-04 |
2015-04-08 |
더 리젠트스 오브 더 유니이버시티 오브 캘리포니아 |
Kinase antagonists
|
AU2007254179B2
(en)
|
2006-05-18 |
2013-03-21 |
Pharmacyclics Llc |
Intracellular kinase inhibitors
|
DE102006026583A1
(en)
|
2006-06-07 |
2007-12-13 |
Bayer Healthcare Aktiengesellschaft |
Aryl-substituted hetero-bicyclic compounds and their use
|
SI2526771T1
(en)
|
2006-09-22 |
2017-06-30 |
Pharmacyclics Llc |
Inhibitors of bruton's tyrosine kinase
|
WO2008054827A2
(en)
|
2006-11-03 |
2008-05-08 |
Pharmacyclics, Inc. |
Bruton's tyrosine kinase activity probe and method of using
|
FI20080352A0
(en)
|
2008-05-09 |
2008-05-09 |
Atacama Labs Oy |
Process for preparing a tablet with high drug content
|
RU2009131749A
(en)
|
2007-01-22 |
2011-02-27 |
Новавакс, Инк. (Us) |
MULTIPHASIC PHARMACEUTICAL COMPOSITIONS OF BADLY SOLUBLE MEDICINAL COMPOUNDS IN WATER TO REDUCE VARIABILITY WHEN RECEIVING AFTER FOOD / NORTH AMERICA AND TO IMPROVE ORAL ORAL BIOAVAILABILITY
|
NL2000640C2
(en)
|
2007-03-05 |
2008-09-08 |
Stichting Wetsus Ct Of Excelle |
Method and system for purifying a liquid.
|
US20120101114A1
(en)
|
2007-03-28 |
2012-04-26 |
Pharmacyclics, Inc. |
Inhibitors of bruton's tyrosine kinase
|
EP2560007A1
(en)
|
2007-03-28 |
2013-02-20 |
Pharmacyclics, Inc. |
Identification of bruton's tyrosine kinase inhibitors
|
US20120065201A1
(en)
|
2007-03-28 |
2012-03-15 |
Pharmacyclics, Inc. |
Inhibitors of bruton's tyrosine kinase
|
US20090010911A1
(en)
|
2007-04-06 |
2009-01-08 |
Iowa State University Research Foundation, Inc. |
Methods and compositions for affecting cyclophilin a regulation of kinases in modulating cellular activities
|
PE20130325A1
(en)
|
2007-04-27 |
2013-03-18 |
Purdue Pharma Lp |
DERIVATIVES OF PIPERIDINE, PIPERAZINE OR TETRAHYDROPYRIDYL AS ANTAGONISTS OF TRPV1
|
MX2010001244A
(en)
|
2007-07-30 |
2010-08-31 |
Ardea Biosciences Inc |
Derivatives of n-(arylamino) sulfonamides including polymorphs as inhibitors of mek as well as compositions, methods of use and methods for preparing the same.
|
EP2214486A4
(en)
|
2007-10-19 |
2011-03-09 |
Avila Therapeutics Inc |
Heteroaryl compounds and uses thereof
|
ES2499017T3
(en)
|
2007-10-23 |
2014-09-26 |
F. Hoffmann-La Roche Ag |
New kinase inhibitors
|
US8426441B2
(en)
|
2007-12-14 |
2013-04-23 |
Roche Palo Alto Llc |
Inhibitors of bruton's tyrosine kinase
|
US20150152115A1
(en)
|
2007-12-27 |
2015-06-04 |
Pharmacyclics, Inc. |
Inhibitors of bruton's tyrosine kinase
|
CA2905541C
(en)
|
2008-01-09 |
2020-02-11 |
Charleston Laboratories, Inc. |
Pharmaceutical compositions comprising an antiemetic and an opioid analgesic
|
US20110136883A1
(en)
|
2008-04-09 |
2011-06-09 |
Lek Pharmaceuticals D.D. |
Granulation of active pharmaceutical ingredients
|
US8808742B2
(en)
|
2008-04-14 |
2014-08-19 |
Ardea Biosciences, Inc. |
Compositions and methods for preparing and using same
|
EP2123626A1
(en)
|
2008-05-21 |
2009-11-25 |
Laboratorios del Dr. Esteve S.A. |
Co-crystals of duloxetine and co-crystal formers for the treatment of pain
|
KR101892989B1
(en)
|
2008-06-27 |
2018-08-30 |
셀젠 카르 엘엘씨 |
Heteroaryl compounds and uses thereof
|
CA2730930C
(en)
|
2008-07-16 |
2015-01-13 |
Pharmacyclics, Inc. |
Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors
|
US8633311B2
(en)
|
2008-07-29 |
2014-01-21 |
Frontier Scientific, Inc. |
Topical application of porphyrins for killing or preventing the growth of bacteria or fungi on a mammal
|
PL2349220T3
(en)
*
|
2008-10-09 |
2012-12-31 |
Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi |
Using of organic solvents in wet granulation of moxifloxacin
|
US8426428B2
(en)
|
2008-12-05 |
2013-04-23 |
Principia Biopharma, Inc. |
EGFR kinase knockdown via electrophilically enhanced inhibitors
|
WO2010068806A1
(en)
|
2008-12-10 |
2010-06-17 |
Cgi Pharmaceuticals, Inc. |
Amide derivatives as btk inhibitors in the treatment of allergic, autoimmune and inflammatory disorders as well as cancer
|
JP5656976B2
(en)
|
2009-04-29 |
2015-01-21 |
ローカス ファーマシューティカルズ インコーポレイテッド |
Pyrrolotriazine compounds
|
CN102713618B
(en)
|
2009-09-16 |
2015-07-15 |
新基阿维罗米克斯研究公司 |
Protein kinase conjugates and inhibitors
|
US7718662B1
(en)
|
2009-10-12 |
2010-05-18 |
Pharmacyclics, Inc. |
Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase
|
PT2578585T
(en)
|
2010-05-31 |
2016-09-23 |
Ono Pharmaceutical Co |
Purinone derivative as btk kinase inhibitor
|
US20120071497A1
(en)
*
|
2010-06-03 |
2012-03-22 |
Pharmacyclics, Inc. |
Methods of treating abc-dlbcl using inhibitors of bruton's tyrosine kinase
|
CA3154024C
(en)
|
2010-06-03 |
2024-02-27 |
Pharmacyclics Llc |
Use of inhibitors of bruton's tyrosine kinase (btk) in the treatment of relapsed or refractory follicular lymphoma
|
US8957065B2
(en)
|
2010-06-23 |
2015-02-17 |
Hanmi Science Co., Ltd |
Fused pyrimidine derivatives for inhibition of tyrosine kinase activity
|
JP6068340B2
(en)
|
2010-08-10 |
2017-01-25 |
セルジーン アヴィロミクス リサーチ, インコーポレイテッド |
Besylate of BTK inhibitor
|
EP3053924A1
(en)
|
2010-08-12 |
2016-08-10 |
Boehringer Ingelheim International Gmbh |
6-cycloalkyl-1, 5-dihydro-pyrazolo [3, 4-d]pyrimidin-4-one derivatives and their use as pde9a inhibitors
|
US8541391B2
(en)
|
2010-10-28 |
2013-09-24 |
Viropharma Incorporated |
Crystalline phases of 5,6-dichloro-2-(isopropylamino)-1-β-L-ribofuranosyl-1H-benzimidazole
|
US8501484B2
(en)
|
2011-03-14 |
2013-08-06 |
Los Alamos National Security, Llc |
Preparation of cerium halide solvate complexes
|
MX2011004759A
(en)
|
2011-05-04 |
2012-11-21 |
Senosiain S A De C V Lab |
Novel antibiotic solid forms.
|
EP2710005B1
(en)
|
2011-05-17 |
2016-10-05 |
Principia Biopharma Inc. |
Tyrosine kinase inhibitors
|
WO2013012959A1
(en)
*
|
2011-07-18 |
2013-01-24 |
Tokai Pharmaceuticals, Inc. |
Novel compositions and methods for treating prostate cancer
|
PE20181272A1
(en)
|
2011-09-02 |
2018-08-03 |
Incyte Holdings Corp |
HETEROCICLYLAMINES AS PI3K INHIBITORS
|
US8377946B1
(en)
|
2011-12-30 |
2013-02-19 |
Pharmacyclics, Inc. |
Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
|
EP4218740A1
(en)
|
2012-01-13 |
2023-08-02 |
XSpray Pharma AB (publ) |
Novel compositions
|
US8501724B1
(en)
|
2012-01-31 |
2013-08-06 |
Pharmacyclics, Inc. |
Purinone compounds as kinase inhibitors
|
JP5514256B2
(en)
|
2012-05-18 |
2014-06-04 |
株式会社東芝 |
Magnetic memory element and manufacturing method thereof
|
MY194911A
(en)
|
2012-06-04 |
2022-12-22 |
Pharmacyclics Llc |
Crystalline forms of a bruton's tyrosine kinase inhibitor
|
KR102150432B1
(en)
|
2012-06-18 |
2020-09-01 |
프린시피아 바이오파마, 인코퍼레이티드 |
Reversible covalent pyrrolo- or pyrazolopyrimidines useful for the treatment cancer and autoimmune diseases
|
WO2014004707A1
(en)
*
|
2012-06-29 |
2014-01-03 |
Principia Biopharma Inc. |
Formulations comprising ibrutinib
|
MX2015001081A
(en)
|
2012-07-24 |
2015-10-14 |
Pharmacyclics Inc |
Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk).
|
CN103121999A
(en)
|
2012-08-29 |
2013-05-29 |
苏州迪飞医药科技有限公司 |
Method for synthesizing tyrosine kinase inhibitor PCI-32765
|
PE20151495A1
(en)
|
2012-11-15 |
2015-10-23 |
Pharmacyclics Inc |
PYRROLOPYRIMIDINE COMPOUNDS AS KINASE INHIBITORS
|
CN111317821A
(en)
|
2013-04-08 |
2020-06-23 |
药品循环有限责任公司 |
Ibrutinib combination therapy
|
RU2705204C2
(en)
|
2013-05-30 |
2019-11-06 |
Инфинити Фармасьютикалз, Инк. |
Treating malignant tumors using piz-kinase isoform modulators
|
US20160067241A1
(en)
|
2013-06-13 |
2016-03-10 |
Dennis M. Brown |
Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted naphthalimides such as amonafide for the treatment of immunological, metabolic, infectious, and benign or neoplastic hyperproliferative disease conditions
|
EP3027192A4
(en)
|
2013-08-02 |
2017-03-22 |
Pharmacyclics, LLC |
Methods for the treatment of solid tumors
|
US10253244B2
(en)
|
2013-09-04 |
2019-04-09 |
Halliburton Energy Services, Inc. |
Scale-inhibiting cocrystals for treatment of a subterranean formation
|
CA2922398C
(en)
|
2013-09-12 |
2023-08-29 |
Dana-Farber Cancer Institute, Inc. |
Methods for evaluating and treating waldenstrom's macroglobulinemia
|
CN104447701B
(en)
|
2013-09-17 |
2019-03-22 |
广东东阳光药业有限公司 |
Pyrazole derivatives and application thereof
|
BR112016009200A8
(en)
|
2013-10-25 |
2020-03-24 |
Pharmacyclics Llc |
use of a btk inhibitor and a checkpoint immune inhibitor
|
WO2015071432A1
(en)
|
2013-11-14 |
2015-05-21 |
Sandoz Ag |
Pharmaceutical compositions of ibrutinib
|
CN103694241A
(en)
|
2013-11-27 |
2014-04-02 |
苏州晶云药物科技有限公司 |
Novel crystal form A of PCI-32765 and preparation method thereof
|
WO2015095772A2
(en)
|
2013-12-20 |
2015-06-25 |
Emory University |
Formulations and methods for targeted ocular delivery of therapeutic agents
|
CN106008514A
(en)
|
2014-01-29 |
2016-10-12 |
苏州晶云药物科技有限公司 |
New crystal form of ibrutinib and preparation method of new crystal form
|
EA201691582A1
(en)
|
2014-02-07 |
2017-01-30 |
Оспекс Фармасьютикалз, Инк. |
NEW PHARMACEUTICAL PREPARATIONS
|
WO2015123654A1
(en)
|
2014-02-17 |
2015-08-20 |
The Cleveland Clinic Foundation |
Amine passivated nanoparticles for cancer treatment and imaging
|
WO2015127261A1
(en)
|
2014-02-21 |
2015-08-27 |
Pharmacyclics, Inc. |
Biomarkers for predicting response of dlbcl to treatment with ibrutinib
|
US20150267752A1
(en)
|
2014-03-19 |
2015-09-24 |
Roller Bearing Company Of America, Inc. |
Bearing outer race having a radially inwardly biased seal
|
CA2942528A1
(en)
|
2014-03-20 |
2015-09-24 |
Pharmacyclics Inc. |
Phospholipase c gamma 2 and resistance associated mutations
|
AU2015237744A1
(en)
|
2014-03-27 |
2016-09-15 |
Wavelength Enterprises Ltd |
Ibrutinib solid forms and production process therefor
|
CN105085529A
(en)
|
2014-05-15 |
2015-11-25 |
广东东阳光药业有限公司 |
Novel crystal form of ibrutinib and preparation method thereof
|
US9127069B1
(en)
*
|
2014-06-11 |
2015-09-08 |
Antecip Bioventures LLC |
Compositions comprising rank/rankl antagonists and related compounds for treating pain
|
US20150110871A1
(en)
|
2014-06-02 |
2015-04-23 |
David Wong |
Gastric retentive tablet compositions
|
US20160008777A1
(en)
|
2014-07-09 |
2016-01-14 |
Novotec Consulting Inc. |
Pharmaceutical compounding kit
|
PT107846B
(en)
|
2014-08-01 |
2019-03-22 |
Hovione Farm S A |
Production of Amorphous Solid Dispersion Nanoparticles by Controlled Co-Precipitation
|
WO2016020697A1
(en)
|
2014-08-06 |
2016-02-11 |
Cipla Limited |
Pharmaceutical compositions of polymeric nanoparticles
|
JP2017523206A
(en)
|
2014-08-07 |
2017-08-17 |
ファーマサイクリックス エルエルシー |
New formulation of breton-type tyrosine kinase inhibitor
|
WO2016025720A1
(en)
|
2014-08-14 |
2016-02-18 |
Assia Chemical Industries Ltd. |
Solid state forms of ibrutinib
|
WO2016050422A1
(en)
|
2014-10-01 |
2016-04-07 |
Ratiopharm Gmbh |
Acid addition salt of ibrutinib
|
CN104523695A
(en)
|
2014-11-12 |
2015-04-22 |
广东东阳光药业有限公司 |
Pharmaceutical composition for treating excessive proliferation diseases
|
CN105640961A
(en)
|
2014-11-18 |
2016-06-08 |
山东瑞禾医药科技有限公司 |
A pharmaceutical composition containing ibrutinib
|
WO2016079216A1
(en)
|
2014-11-20 |
2016-05-26 |
Sandoz Ag |
Physical forms of ibrutinib, a bruton's kinase inhibitor
|
US20150224060A1
(en)
|
2015-01-03 |
2015-08-13 |
David Wong |
Gastric retentive tablet compositions
|
CZ201584A3
(en)
|
2015-02-09 |
2016-08-17 |
Zentiva, K.S. |
Ibrutinib sulfate salt
|
JP2018511580A
(en)
|
2015-03-03 |
2018-04-26 |
ドクター レディズ ラボラトリーズ リミテッド |
Ibrutinib polymorph
|
WO2016141068A1
(en)
|
2015-03-03 |
2016-09-09 |
Pharmacyclics Llc |
Pharmaceutical formulations of bruton's tyrosine kinase inhibtor
|
MA41827A
(en)
|
2015-03-27 |
2018-01-30 |
Pharmacyclics Llc |
SOLVATED FORMS OF A BRUTON TYROSINE KINASE INHIBITOR
|
MA41828A
(en)
|
2015-03-27 |
2018-01-30 |
Pharmacyclics Llc |
CO-CRYSTALS OF A TYROSINE KINASE INHIBITOR FROM BRUTON
|
EP3277688B1
(en)
|
2015-04-02 |
2019-05-08 |
ratiopharm GmbH |
Co-crystals of ibrutinib
|
PT3892302T
(en)
|
2015-04-06 |
2023-11-15 |
Janssen Pharmaceutica Nv |
Compositions containing ibrutinib
|
CN105294696A
(en)
|
2015-11-19 |
2016-02-03 |
上海创诺医药集团有限公司 |
Novel crystal forms of ibrutinib and preparation method thereof
|
CN105440040B
(en)
|
2015-12-23 |
2018-03-13 |
浙江京新药业股份有限公司 |
The purification process of Buddhist nun is replaced according to Shandong
|
MA43649A
(en)
*
|
2016-01-19 |
2018-11-28 |
Janssen Pharmaceutica Nv |
FORMULATIONS / COMPOSITIONS INCLUDING A BTK INHIBITOR
|
CN108472258A
(en)
*
|
2016-01-19 |
2018-08-31 |
詹森药业有限公司 |
Include preparation/composition of BTK inhibitor
|
CN105646499A
(en)
|
2016-03-01 |
2016-06-08 |
孙霖 |
Crystal form G of ibrutinib and preparation method
|
CN105646498A
(en)
|
2016-03-01 |
2016-06-08 |
孙霖 |
Crystal form F of ibrutinib and preparation method
|
CN105646484A
(en)
|
2016-03-01 |
2016-06-08 |
孙霖 |
Crystal form B and preparation method
|
CN106619643A
(en)
|
2016-11-11 |
2017-05-10 |
上海雅本化学有限公司 |
Pharmaceutical composition containing ibrutinib
|